Friday 6 November 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue: +1.33%
EPS: +418.2%
Free cash flow: −6.83%
Total debt: −42.2%

Quarter to June 2026, against a year earlier

72.76 0.10 +0.14%

Follow TECH

Alert me

Market cap: $11.4B
P/E: 62.2×
Fwd P/E: 54.2×
Dividend yield: 0.44%
F-score: 9/9
Altman Z: 15.50
Beneish M: −2.52
Dividend safety: 78/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bio-Techne Corp (TECH) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2026: revenue by segment, and margins
Protein Sciences	875	71.98%
Diagnostics and Spatial Biology	336	27.68%
Gross margin		65.77%
Operating margin		20.73%
Pre-tax margin		19.81%

Revenue by product or service $m

Line	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Consumables	985 81.08%	972 79.72%	928 80.08%	918 80.74%	891 80.58%	752 80.77%	603 81.58%	589 82.49%	535 83.16%	477 84.64%
Instruments	111 9.11%	112 9.19%	108 9.34%	112 9.86%	121 10.92%	94 10.07%	71 9.67%	68 9.46%	62 9.61%	48 8.48%
Services	94 7.76%	112 9.15%	99 8.56%	86 7.55%	72 6.51%	66 7.13%	47 6.42%	38 5.33%	34 5.31%	24 4.20%
Royalty	25 2.06%	24 1.94%	23 2.01%	21 1.86%	22 1.99%	19 2.02%	17 2.32%	19 2.72%	12 1.92%	15 2.67%
Product and Services	1,190	1,196	1,136	1,116	1,084	912	722	695	631	548
Revenue	1,215	1,220	1,159	1,137	1,106	931	739	714	643	563

Revenue by segment $m

Line	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Protein Sciences	875 71.98%	870 71.35%	831 71.69%	846 74.40%	832 75.28%	705 75.68%	555 75.18%	543 76.07%	482 75.02%	419 74.49%	—	—	—	—	—	—	—	—
Diagnostics and Spatial Biology	336 27.68%	346 28.39%	326 28.16%	293 25.74%	275 24.86%	228 24.46%	185 24.98%	172 24.04%	161 25.06%	144 25.53%	—	—	—	—	—	—	—	—
Biotechnology	—	—	—	—	—	—	—	—	—	—	317 63.59%	308 68.20%	285 79.70%	288 92.78%	293 93.23%	270 93.21%	251 93.16%	246 93.37%
Diagnostics	—	—	—	—	—	—	—	—	—	—	104 20.94%	78 17.22%	73 20.30%	22 7.22%	21 6.77%	20 6.79%	18 6.84%	18 6.63%
Protein Platforms	—	—	—	—	—	—	—	—	—	—	77 15.50%	66 14.65%	0 0.00%	0 0.00%	—	—	—	—
Revenue	1,215	1,220	1,159	1,137	1,106	931	739	714	643	563	499	452	358	311	315	290	269	264

Operating income by segment $m, and margin

	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Protein Sciences	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Diagnostics and Spatial Biology	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Biotechnology	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Diagnostics	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Protein Platforms	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
United States	635 52.29%	683 56.02%	658 56.75%	642 56.52%	614 55.55%	502 53.93%	404 54.75%	391 54.79%	346 53.86%	313 55.63%	276 55.28%	245 54.22%	190 53.21%	164 52.90%	172 54.78%	160 55.13%	148 55.06%	147 55.79%
EMEA, excluding United Kingdom	294 24.22%	266 21.83%	241 20.83%	220 19.37%	219 19.81%	204 21.94%	155 21.02%	156 21.82%	149 23.11%	125 22.22%	103 20.65%	104 23.04%	—	—	—	—	—	—
Greater China	104 8.56%	100 8.24%	99 8.58%	114 10.02%	112 10.17%	88 9.40%	69 9.31%	58 8.10%	48 7.46%	39 6.94%	36 7.25%	35 7.72%	19 5.28%	14 4.54%	11 3.62%	8 2.86%	7 2.52%	6 2.14%
APAC, excluding Greater China	86 7.06%	77 6.33%	74 6.38%	73 6.44%	76 6.89%	69 7.41%	60 8.17%	53 7.41%	48 7.53%	41 7.36%	38 7.64%	24 5.31%	—	—	—	—	—	—
United Kingdom	56 4.63%	55 4.50%	50 4.31%	49 4.35%	49 4.40%	41 4.40%	30 4.12%	35 4.90%	34 5.24%	28 5.04%	28 5.67%	32 7.14%	55 15.41%	—	—	—	—	—
Rest of World	39 3.23%	38 3.08%	36 3.15%	37 3.30%	35 3.19%	27 2.92%	19 2.63%	21 2.98%	18 2.81%	16 2.80%	17 3.50%	12 2.56%	19 5.22%	15 4.91%	15 4.69%	13 4.63%	13 4.92%	—
Europe Other than U.K.	—	—	—	—	—	—	—	—	—	—	—	—	42 11.74%	—	—	—	—	—
Other Asia	—	—	—	—	—	—	—	—	—	—	—	—	33 9.14%	29 9.21%	26 8.26%	25 8.52%	22 8.32%	—
Europe	—	—	—	—	—	—	—	—	—	—	—	—	—	88 28.43%	90 28.66%	84 28.86%	78 29.18%	79 30.07%
Other Areas	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	32 11.99%
Revenue	1,215	1,220	1,159	1,137	1,106	931	739	714	643	563	499	452	358	311	315	290	269	264

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.